Reference Detail

Ref Type

Journal Article

PMID

(26267534)

Authors

Herrero A, Pinto A, Colon-Bolea P, Casar B, Jones M, Agudo-Ibanez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizan EM, Horvath Z, Orfi L, Pineda-Lucena A, Bony E, Keri G, Rivas G, Pazos A, Gozalbes R, Palmer HG, Hurlstone A, Crespo P

Title

Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.

Journal	Vol	Issue	Date	Pages	Journal Short Title
Cancer cell	28	2	2015 Aug 10	170-82	Cancer Cell

URL

Abstract Text

Nearly 50% of human malignancies exhibit unregulated RAS-ERK signaling; inhibiting it is a valid strategy for antineoplastic intervention. Upon activation, ERK dimerize, which is essential for ERK extranuclear, but not for nuclear, signaling. Here, we describe a small molecule inhibitor for ERK dimerization that, without affecting ERK phosphorylation, forestalls tumorigenesis driven by RAS-ERK pathway oncogenes. This compound is unaffected by resistance mechanisms that hamper classical RAS-ERK pathway inhibitors. Thus, ERK dimerization inhibitors provide the proof of principle for two understudied concepts in cancer therapy: (1) the blockade of sub-localization-specific sub-signals, rather than total signals, as a means of impeding oncogenic RAS-ERK signaling and (2) targeting regulatory protein-protein interactions, rather than catalytic activities, as an approach for producing effective antitumor agents.

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach
No data available in table

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role
No data available in table

Filter rows:

Showing 1 to 1 of 1 entries

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
DEL-22379	DEL-22379	5	0

Showing 1 to 1 of 1 entries

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
DEL-22379			ERK Inhibitor (pan) 21	DEL-22379 inhibits ERK dimerization, resulting in decreased extranuclear ERK signaling and potentially leading to reduced growth of ERK pathway-driven tumors (PMID: 26267534, PMID: 32377992).

Showing 1 to 1 of 1 entries

Filter rows:

Showing 0 to 0 of 0 entries

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance
No data available in table

Filter rows:

Showing 1 to 13 of 13 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
BRAF V600E	colorectal adenocarcinoma	sensitive	DEL-22379	Preclinical - Pdx	Actionable	In a preclinical study, DEL-22379 inhibited tumor growth in a colorectal adenocarcinoma patient-derived xenograft model harboring BRAF V600E (PMID: 26267534).	26267534
BRAF V600E	melanoma	sensitive	DEL-22379	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DEL-22379 inhibited growth of melanoma cells harboring BRAF V600E with high levels of ERK dimerization in culture and inhibited tumor progression in melanoma xenograft models harboring BRAF V600E (PMID: 26267534).	26267534
BRAF V600E	melanoma	conflicting	Mirdametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gomekli (mirdametinib) inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).	26267534
BRAF V600E MAP2K1 I103N	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534).	26267534
BRAF V600E MAP2K1 I103N	melanoma	resistant	Mirdametinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of MAP2K1 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by Gomekli (mirdametinib) in cell culture (PMID: 26267534).	26267534
BRAF V600E MAP2K1 L115P	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 26267534).	26267534
BRAF V600E NRAS G12V	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and over expressing NRAS G12V in culture (PMID: 26267534).	26267534
BRAF V600E	colorectal cancer	sensitive	Mirdametinib	Preclinical	Actionable	In a preclinical study, Gomekli (mirdametinib) inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).	26267534
BRAF V600E	colorectal cancer	sensitive	SCH772984	Preclinical	Actionable	In a preclinical study, SCH772984 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).	26267534
BRAF V600E	melanoma	sensitive	SCH772984	Preclinical	Actionable	In a preclinical study, SCH772984 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).	26267534
BRAF V600E MAP2K1 L115P	melanoma	resistant	Mirdametinib	Preclinical	Actionable	In a preclinical study, overexpression of MAP2K1 L115P in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by Gomekli (mirdametinib) in cell culture (PMID: 26267534).	26267534
BRAF V600E NRAS G12V	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534).	26267534
HRAS G12V	melanoma	sensitive	CI-1040	Preclinical	Actionable	In a preclinical study CI-1040 (PD-184352) inhibited melanoma progression in a transgenic zebrafish model of melanoma expressing HRAS G12V (PMID: 26267534).	26267534

Showing 1 to 13 of 13 entries

Filter rows:

Reference Detail

Contact

Filtering

Sorting